[Skip to content]

European Parkinson's Disease Association
Search our Site

Research papers


Mechanisms research papers

  • Brain skeleton RNA metabolism in the pathogenesis of Parkinsons diseaseIt is anticipated that continued studies on the role of RNA metabolism in Parkinsons disease will offer unifying mechanisms for understanding the cause of neuronal dysfunction and degeneration and facilitate the development of novel and rational strategies for treating this debilitating disease. 10 October 2014
  • Blood cells The role of iron in brain ageing and neurodegenerative disordersDuring ageing, different iron complexes accumulate in brain regions associated with motor and cognitive impairment. In various neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, changes in iron homoeostasis result in altered cellular iron distribution and accumulation. 01 October 2014
  • Brain A GCase Chaperone Improves Motor Function in a Mouse Model of SynucleinopathyThese data support the further investigation of pharmacological chaperones that target GCase as a therapeutic approach for sporadic PD and other synucleinopathies, even in the absence of glucocerebrosidase mutations. 01 October 2014
  • Brain Midlife migraine and late-life parkinsonismThese findings suggest there may be a common vulnerability to, or consequences of, migraine and multiple indicators of parkinsonism. Additional genetic and longitudinal observational studies are needed to identify candidate pathways that may account for the comorbid constellation of symptoms. 30 September 2014
  • Brain scan Parkinson's disease and age: The obvious but largely unexplored linkThe risk of Parkinson's disease increases dramatically in individuals over the age of 60 and it is estimated that more than 1% of all seniors have some form of the condition. In this review, authors will highlight some of the central proteins associated with Parkinson's disease and how they may be linked to processes and factors associated with age. 28 September 2014
  • Cells neuron structure Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's diseaseIn conclusion, study findings cast doubt on the pathogenic role of α-synuclein aggregates in elderly, but do suggest that the severity of neurodegeneration and local burden of α-synuclein pathological conditions are closely coupled during disease progression in Parkinson's disease. 15 September 2014
  • Brain activity High-frequency oscillations in Parkinson's disease: Spatial distribution and clinical relevanceAuthors found a focal spatial distribution of high-frequency oscillations with highest power 2 mm below the dorsolateral border of the subthalamic nucleus. Within the subthalamic nucleus, power peaked slightly anterior to the DBS target site. 15 September 2014
  • Neuron Three Mechanisms by which Striatal Denervation Causes Breakdown of Dopamine SignalingThis analysis provides a quantitative, physiologically consistent view of the early and late stages of PD, the effect of main therapeutic medications, and potential side effects. The mechanisms described here may also provide an explanation to currently inexplicable pathological phenomena such as psycho stimulant-induced contraversive rotations in animal models. 10 September 2014
  • DNA Puerarin protects dopaminergic neurons in Parkinson's disease modelsThese data indicated that puerarin alleviated the oxidative stress and apoptosis in a PD cellular model, protected the dopaminergic neurons against rotenone toxicity and decreased the abnormal protein overexpressing in PD animal models. These findings suggest that puerarin may develop into a neuroprotective alternative for patients with PD. 10 September 2014
  • Neuron Early-onset Parkinson's disease due to PINK1 p.Q456X mutation - Clinical and functional studyConclusions The PINK1 p.Q456X mutation leads to a decrease in mRNA and a loss of protein function. The foot dystonia and gait disorders seen at disease onset in affected members of our family, which were accompanied by parkinsonism had a similar clinical presentation to what has been described in previous reports of PINK1 mutation carriers. 03 September 2014
Page: [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [+11]